期刊文献+

卵巢肿瘤干细胞中趋化因子表达与细胞侵袭后的转移能力 被引量:2

Chemokine expression in the ovarian tumor stem cells and cell invasion and metastasis
下载PDF
导出
摘要 背景:利用趋化因子或趋化性多肽招募免疫效应细胞汇集于肿瘤,激发抗肿瘤免疫的方法有望成为肿瘤治疗的新策略。目的:探讨卵巢肿瘤细胞中趋化因子的表达与细胞侵袭转移能力关系。方法:采用RT-PCR方法检测卵巢肿瘤细胞系SW626和Anglne细胞株中CXCR4的表达,然后在Transwell小室检测CXCL12与CXCL12/CXCR4对SW626细胞趋化活性和侵袭活性的影响。结果与结论:RT-PCR检测结果提示SW626卵巢细胞株中有CXCR4分子的表达,而在Anglne细胞中CXCR4无表达。CXCR4的表达能促使卵巢肿瘤细胞中发生趋化与侵袭转移的细胞数目增多,而加入CXCR4中和抗体时,能抑制上述效果。结果可见卵巢肿瘤细胞干细胞趋化因子CXCL12对SW626细胞有明显的趋化活性和侵袭转移活性,其活性是通过其受体CXCR4介导的。 BACKGROUND:The method that using chemokine or chemotactic polypeptide to recruit immune effector cells to converge in tumor cells to arise anti-tumor immunity is expected to become a new strategy for tumor treatment.OBJECTIVE:To discuss the effects of chemokine expression on the invasion and metastasis in the ovarian tumor stem cells for giving new ideas of ovarian cancer research.METHODS:Expression of CXCR4 in ovarian cancer cell line SW626 was detected by reverse transcriptase-polymerase chain reaction(RT-PCR).Transwell room was used to detect the effects of CXCL12 and CXCL12/CXCR4 on chemotaxic invasion and metastasis of SW626 cells.RESULTS AND CONCLUSION:RT-PCR confirmed that there was CXCR4 expression in the SW626 cell lines,but no expression was found in the Anglne cells.CXCR4 expression could increase the number of ovarian tumor stem cells subjected to chemotactic invasion and metastasis,while CXCR4 addition could inhibit above-mentioned effects.CXCR12,a chemotatic factor of ovarian tumor stem cells,can promote the chemotaxic activity and invasion and metastasis activity mediated by CXCR4 receptor.
作者 孙晖
机构地区 南阳市中心医院
出处 《中国组织工程研究》 CAS CSCD 2012年第41期7669-7672,共4页 Chinese Journal of Tissue Engineering Research
  • 相关文献

参考文献20

二级参考文献37

  • 1王琪,李力,黎丹戎,张伟,韦霄,张洁清,唐勇.应用飞行时间质谱技术结合蛋白芯片筛选卵巢恶性肿瘤患者的血清标志物[J].中华妇产科杂志,2006,41(8):544-548. 被引量:33
  • 2吴江宏,王亚农,欧周罗,师英强.胃癌患者术前外周血CCL18的检测及其意义[J].中国癌症杂志,2006,16(10):835-837. 被引量:9
  • 3Judith YMNE, Marie-Chrlstine WG, Jan HMS, et al. Clinical proteomics: searching for better turnout markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci, 2006, 27: 251-259.
  • 4Zhang Z, Bast BC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res, 2004, 15: 5882-5890.
  • 5Kodera M, Hasegawa M, Komura K, et al. Serum pulmonary and activation regulated chemokine /CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum, 2005, 52 : 2889-2896.
  • 6StruyfS, Schutyser E, Gouwy M, et al. CCL18 /CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am J Pathol, 2003, 163 : 2065-2075.
  • 7Leung SY, Yuen ST, Chu KM, et al. Expression profiling identifies chemokine (C2C motif) ligand 18 as an independent prognostic indicator in gastric cancer. Gastroenterology, 2004, 127 : 457-469.
  • 8Schutyser E, Struyf S, Proost P, et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18 /pulmonary and activation2regulated chemokine in ovarian carcinoma. J Biol Chem, 2002, 277: 245842-24593.
  • 9Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA, 1996, 93:136-140.
  • 10Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res, 2004, 10: 3937-3942.

共引文献26

同被引文献10

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部